Dr. Evgenii Shumilov – Oncology and Hematology – Outstanding Scientist Award

Posted on by Innovator Awards

Dr. Evgenii Shumilov - Oncology and Hematology - Outstanding Scientist Award

University Hospital Münster Medical Clinic A -  Germany

Author Profile 

ORCID 

🎓 Early academic pursuits

Dr. Evgenii Shumilov began his academic journey in kirovskaya gebiet, russland, where he completed his general secondary education in june 2006. driven by a passion for human biology and clinical care, he enrolled in the staatliche medizinische akademie in kirow in 2006. the following year, he transitioned to the esteemed st. petersburger staatliche medizinische universität i.p. pawlow, where he pursued his degree in human medicine until 2012. during this formative period, he developed a growing interest in the biochemical pathways influencing addiction, which would later shape his doctoral research.

🏥 Professional endeavors

His professional career started immediately after his graduation with a clinical internship in internal medicine at the universitätsklinikum st. petersburg i.p. pawlow. dr. shumilov then completed a specialized clinical training in oncology at the renowned n.n. petrow institute for oncology. from 2015 to 2021, he continued his facharztausbildung (specialist training) in internal medicine, hematology, and oncology at the universitätsmedizin göttingen. since 2021, he has served in various capacities at the universitätsklinikum münster, advancing to oberarzt (senior physician) in the day clinic of oncology by 2022. his role requires the coordination of clinical therapies, implementation of modern diagnostics, and integration of interdisciplinary care — akin to the precision and optimization seen in power electronics systems.

🔬 Contributions and research focus

Dr. Shumilov has made significant scientific contributions in the field of pharmacology and hemato-oncology. between 2012 and 2015, he pursued a doctoral program in pharmacology at the anichkow institute for experimental medicine, focusing on neuropharmacology and the role of orexin-1 receptors in addiction — a study that mirrors the regulatory mechanisms of feedback and control in power electronics. in 2018, he earned a second doctorate (dr. med.) from the university of bern, switzerland, with a dissertation exploring genetic mutations bridging Oncology and Hematology hematopoietic lineages and solid tumors in the age of high-throughput sequencing. his work has helped redefine diagnostic paradigms in clinical oncology.

🌍 Impact and influence

Dr. Shumilov’s cross-disciplinary expertise bridges clinical practice and molecular diagnostics. his innovative thinking, reflected in his dual doctoral research and international academic Oncology and Hematology exposure, positions him as a leader in precision medicine. like the transformative role of power electronics in renewable energy systems, his influence lies in optimizing diagnostic accuracy and tailoring therapies for oncology patients. he is actively mentoring junior clinicians, integrating translational research into routine care, and contributing to academic networks across europe and russia.

📚 Academic citations and recognitions

He has received notable academic recognition, including a posterpreis at the dgho annual meeting in stuttgart (2017), and the prestigious dfg “clinician scientist” funding from 2020 to 2021. his scientific contributions are frequently cited in studies on neuropharmacology and next-generation sequencing diagnostics. his work on orexin receptors and hematologic malignancies Oncology and Hematology continues to influence both pharmacologic models and clinical protocols.

🌱 Legacy and future contributions

Dr. Shumilov’s legacy lies in his capacity to interweave basic science with clinical oncology. he is currently leading projects that integrate high-throughput genomic data with patient-specific therapy plans, aiming for breakthroughs in hematologic and solid tumor treatments. with a forward-looking perspective, he is exploring digital integration and ai-assisted diagnostics, similar to how power electronics revolutionize control in automated systems. his future vision includes strengthening international research collaborations and expanding educational programs for medical scientists.

Notable Publications 

  • Title: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
    Author(s): Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, et al.
    Journal: Blood Advances

  • Title: Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
    Author(s): Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
    Journal: Leukemia & Lymphoma

  • Title: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
    Author(s): Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp B. Staber, Paolo Mazzeo, Corinna Leng, et al.
    Journal: Blood Advances

  • Title: Benefit of repeated COVID‐19 vaccination for patients with B‐cell malignancies
    Author(s): Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
    Journal: British Journal of Haematology

  • Title: Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
    Author(s): Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich
    Journal: Cancers

Assoc. Prof. Dr. Jun Xiu sheng – Cancer treatment – Best Researcher Award

Posted on by Innovator Awards

Assoc. Prof. Dr. Jun Xiu sheng - Cancer treatment - Best Researcher Award

The First Affiliated Hospital of Dalian Medical University - China 

Author Profile 

SCOPUS 

ORCID 

🎓 Early academic pursuits

Jun Xiu sheng began his academic journey with a strong foundation in clinical medicine. from 2006 to 2011, he pursued a seven-year undergraduate program in clinical medicine at dalian medical university, followed by graduate studies from 2011 to 2013 at the same institution. in 2013, he embarked on a ph.d. in oncology at the graduate school of dalian medical university, sharpening his focus on cancer biology and therapy. his academic path was further enriched through a prestigious exchange scholar program at the medical university of wisconsin, usa, from 2015 to 2016, where he gained international exposure and research insight.

🩺 Professional endeavors

After completing his advanced education, jun xiu sheng joined the first affiliated hospital of dalian medical university. he served as a resident in the department of radiotherapy from 2016 to 2018 and quickly rose through the ranks to become an attending physician (2018–2020). since december 2020, he has held the position of deputy chief physician, where he also serves as an associate professor. his clinical expertise lies in radiation oncology, contributing to the development of novel therapeutic strategies in cancer care. jun xiu sheng’s interest in interdisciplinary approaches, including those inspired by power electronics systems, has made his clinical methods highly adaptive and innovative.

🔬 Contributions and research focus

With a ph.d. in oncology, jun xiu sheng has dedicated his research efforts to understanding the molecular and cellular mechanisms behind tumor resistance and radiotherapy. his recent work explores how melatonin modulates rna splicing in esophageal cancer cells, potentially increasing radiotherapy sensitivity. melatonin, known for its use in treating central nervous system Cancer treatment diseases, has shown promise in suppressing tumor growth. through bioinformatics and rna-seq analysis, jun xiu sheng has investigated the role of variable splicing in radiation resistance, aiming to unlock therapeutic pathways to improve cancer treatment outcomes. integrating ideas from power electronics systems, he also explores regulatory networks in tumor biology.

🌍 Impact and influence

Jun Xiu sheng’s research has not only advanced our understanding of cancer biology but also influenced therapeutic strategies in radiation oncology. by uncovering mechanisms related to rna Cancer treatment variable splicing and the effects of melatonin on tumor cells, he has provided critical insight into resistance pathways. his collaborative roles in national-level projects, including the national natural science foundation of china, have elevated his profile within the academic and medical communities. his interdisciplinary thinking, including applying models from power electronics, offers new paradigms in cancer signal processing and therapy modulation.

📚 Academic cites

Jun Xiu sheng has participated in several major research projects. he contributed to a study on circular rna generation funded by the national natural science foundation of china, and another Cancer treatment on the function of rna variable splicing in tumor radiotherapy resistance. as a principal investigator, he led projects on aspirin-induced rna splicing in lung cancer and on the immune regulation of head and neck squamous cell carcinoma (hnscc). his ongoing research into esophageal cancer immunotherapy and prognosis demonstrates a sustained commitment to scholarly contribution and scientific innovation.

🧬 Legacy and future contributions

Looking forward, jun xiu sheng is committed to deepening his exploration of tumor microenvironments, radiotherapy resistance mechanisms, and immune system interactions in cancer. his current projects funded by liaoning provincial programs and education departments reflect his active role in shaping the future of oncology. he envisions integrating computational and systemic models—akin to feedback loops found in power electronics—to decode complex biological responses in tumors. his legacy will be defined by a blend of rigorous scientific inquiry, clinical excellence, and forward-thinking applications in precision medicine.

Notable Publications 

Title: The role of oncostatin M in esophageal cancer and its potential as a prognostic marker
Author(s): Guangxiang Ding, Xianwei Li, Hongtao Yin, Bing Sun, Junxiu Sheng
Journal: Computers in Biology and Medicine, 2025

Dr. Frédérique Vegran – immuno oncology –  Best Researcher Award

Posted on by Innovator Awards

Dr. Frédérique Vegran - immuno oncology -  Best Researcher Award

INSERM - France

Author Profile 

GOOGLE SCHOLAR 

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

🧪 Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications 

  1. Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
    Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
    Journal: The Journal of Clinical Investigation

  2. Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis
    Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
    Journal: Cancer Research

  3. Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
    Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
    Journal: Nature Medicine

  4. Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
    Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
    Journal: PLOS ONE

  5. Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
    Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
    Journal: Nature Immunolog

Prof. Jerzy trojan – Immuno – gene therapy – Excellence in Innovation

Posted on by Innovator Awards

Prof. Jerzy trojan - Immuno - gene therapy - Excellence in Innovation

CEDEA/ICGT and INSERM/Univ. Paris-Saclay - France

Author Profile

ORCID

Early academic pursuits 🎓

Jerzy trojan completed his doctorate d’état ès sciences (hdr) at the prestigious sorbonne - p&m curie. during this formative period, he laid the groundwork for his future contributions to biomedical science, specifically in the field of cancerology. his early research endeavors, characterized by a rigorous scientific approach, focused on critical aspects of oncology and laid the foundation for his later groundbreaking work.

Professional endeavors 🏥

Jerzy has held various esteemed positions throughout his career, reflecting his commitment to advancing cancer research. he is currently a visiting professor at the insitm, cancer center, and paris-saclay university in villejuif, france, where he has been since 2019. before this, he served as president and research director at the international cancer gene therapy and oncology diagnostics center (ceadea) in bogota, colombia, and has also held prominent roles in institutions across the usa and europe, including case western reserve university and the sidney kimmel cancer center. these diverse experiences have equipped him with a comprehensive understanding of both the scientific and clinical aspects of cancer treatment.

Contributions and research focus 🔬

Dr. trojan is best known for establishing cancer gene therapy, particularly immuno-gene therapy, as a pivotal domain within oncology. his pioneering research, highlighted in publications from 1993, led to significant advancements in the treatment of glioblastoma, showcasing the therapeutic potential of gene therapy. Immuno - gene therapy additionally, he explored the intersection between neuro-ontogenesis and neuro-oncogenesis, identifying afp and igf-i as novel biomarkers, which have implications for understanding central nervous system differentiation and cancer progression.

Accolades and recognition 🏆

In recognition of his substantial contributions to biomedical science, jerzy was elected as a member of the prestigious french academy of medicine (anm) in paris in 2017. his extensive body of work includes nearly 370 publications, encompassing 140 articles, 102 book chapters, and four books, which have garnered over 3,500 Immuno - gene therapy citations. this impressive scholarly output underscores his impact and influence in the field of cancer research.

Impact and influence 🌍

Dr. trojan's research has significantly shaped the landscape of cancer therapy, particularly in immunotherapy. his establishment of immuno-gene therapy has opened new avenues for treating aggressive cancers, thus influencing both academic research and clinical practices. his work has not only contributed to theoretical Immuno - gene therapy advancements but has also informed practical applications that benefit patients facing challenging diagnoses.

Legacy and future contributions 🔮

With an enduring commitment to advancing cancer research, jerzy trojan continues to influence the field through his current role as a visiting professor and research director. his legacy is evident in the ongoing projects aimed at improving cancer treatment outcomes, particularly through innovative therapeutic strategies. as he continues to publish and mentor the next generation of researchers, his contributions will undoubtedly have a lasting impact on the future of oncology and gene therapy.

Notable Publications 

  • Title: Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment
    Author: J. Trojan et al.
    Journal: Medical Research and Its Applications, Vol. 6, Pages 114-127
    DOI: 10.9734/bpi/mria/v6/7520C
    Publication Date: June 3, 2024
  • Title: Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
    Author: J. Trojan
    Journal: Current Medicinal Chemistry, Vol. 31, Pages 1982-2002
    DOI: 10.2174/0109298673231106095141
    Publication Date: March 11, 2024
  • Title: Establishment of Cancer Gene Therapy
    Author: J. Trojan
    Journal: Cambridge Scholars Publishing
    Publication Date: March 2, 2023
  • Title: Neoplastic brain, glioblastoma and immunotherapy
    Author: J. Trojan et al.
    Journal: In: Brain and Spinal Tumors - Primary and Secondary, Ed. L.R. Morgan, F.B. Sarica, InTechOpen
    Publication Date: 2020
  • Title: In vitro technical aspects of Anti–Gene IGF-I vaccines against glioma
    Author: J. Trojan et al.
    Journal: IBR, Vol. 3(1), Pages 43-48
    Publication Date: 2019